Sawai Group Holdings (4887) Fundamentals 2026 — P/E 18.4x, Revenue Analysis | SniperIQ
Sawai Group Holdings (4887) is a JP-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥194.1B, trading at ¥1680.50 on the JPX. This SniperIQ fundamentals page covers Sawai Group Holdings's valuation (P/E 18.4x, P/B 1.1x), profitability (net margin 5.2%), revenue (¥201.7B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Sawai Group Holdings's market cap?
Sawai Group Holdings (4887) has a market capitalization of approximately ¥194.1B, trading at ¥1680.50 on the JPX. Market cap moves with the live share price.
What is Sawai Group Holdings's P/E ratio?
Sawai Group Holdings's trailing twelve-month P/E ratio is 18.4x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Sawai Group Holdings?
Sawai Group Holdings runs a net profit margin of 5.2%, a gross margin of 29.2%, and an operating margin of 10.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Sawai Group Holdings generate?
Sawai Group Holdings reported revenue of ¥201.7B for fiscal year 2026, with net income of ¥10.4B and earnings per share (EPS) of 90.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Sawai Group Holdings pay a dividend?
Sawai Group Holdings offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Sawai Group Holdings financially healthy?
Sawai Group Holdings carries a debt-to-equity ratio of 0.59x and a current ratio of 2.48x, with a market beta of 0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Sawai Group Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Sawai Group Holdings (4887) the key facts are: market cap ¥194.1B, P/E 18.4x, revenue ¥201.7B, 52-week range 1591-2447. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Sawai Group Holdings's full fundamentals live
Get Sawai Group Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.